AKLI Overview

Akili, Inc. (Akili) is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company is focused on developing and commercializing technologies designed to directly target the physiology of the brain. The Company’s software-based medicine is designed to directly target brain function and is delivered through engaging consumer entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain. The Company’s products include EndeavorRx, Selective Stimulus Management Engine (SSME), Body Brain Trainer (BBT) and Spatial Navigation (SNAV) Engine. EndeavorRx product is measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. SSME is specifically engineered to target and activate the systems in the brain that play a key role in attention function.

Wall Street analysts forecast AKLI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKLI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Akili Inc revenue for the last quarter amounts to 383.00K USD, increased 238.94 % YoY.

Akili Inc. EPS for the last quarter amounts to -0.12 USD, decreased -55.56 % YoY.

Akili Inc (AKLI) has 68 emplpoyees as of February 10 2026.

Today AKLI has the market capitalization of 34.25M USD.